JP Llanos Ackert, MD, C Ambrose, MD: New Data Support Tezepelumab for AsthmaMay 31st 2023
Investigators Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose share insight on the efficacy of tezepelumab in severe, uncontrolled asthma, and baseline predictors of enhanced response which support tezepelumab as a promising biologic treatment option.
Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable Potential in Treating Relapsed AMLMay 31st 2023
Celularity's clinical trial of CYNK-001 for relapsed and refractory AML showed excellent tolerability, significant graft-versus-leukemia effects, and potential for flexible therapeutic development.
Hollis O'Neal, MD: FDA-Approved Test Can Identify Early SepsisMay 30th 2023
Late-breaking data validates the FDA clearance of Cytovale's IntelliSep test, demonstrating its potential to aid in the early detection of sepsis in US emergency departments, with the aim of improving patient outcomes.
Hollis O'Neal, MD: Late Breaking Data on Diagnostic Test for Sepsis IntelliSepMay 29th 2023
Late-breaking data from ATS 2023 show new positive evidence of the innovative in-vitro diagnostic tool IntelliSep test that measures the viscoelastic properties of leukocytes, showing promising results for rapid sepsis diagnosis in EDs.
Victor Kim, MD: Addressing Comorbidities and Advancing COPD CareMay 28th 2023
Data indicates that addressing mood disorders in patients not only improves mood symptoms but also demonstrates positive effects on certain cardiac events, suggesting benefits for both mental and physical well-being.
Cedric Rutland, MD: Mechanisms Behind Immunology, Cellular CommunicationMay 23rd 2023
Dr. Rutland emphasizes the importance of understanding cellular communication and its potential to manipulate disease processes for patient benefit, including the observed link between ILD, inflammation, scarring, and pulmonary hypertension.
No Link Found Between Mental Health, Sleep Quality, and COVID-19 Vaccine ResponseMay 19th 2023
The study revealed that healthcare workers with psychiatric disorders had slightly lower Anti-SARS-CoV-2-Spike IgG levels before their third COVID-19 vaccination, but this effect was mediated by age and body mass index.
Ziritaxestat Fails to Demonstrate Efficacy for Treatment of IPF in 2 TrialsMay 16th 2023
The phase 3 clinical trials evaluating ziritaxestat for treating idiopathic pulmonary fibrosis showed no improvement in clinical outcomes leading to the termination of the trials due to lack of efficacy.